As the role of immunotherapies in treating patients with renal cell carcinoma (RCC) grows, keeping up with the pace of emerging data on combination therapy regimens, effective practices for monitoring and managing immune-related adverse events, and educating patients to empower informed decision-making can be challenging. This CME, CNE, and CPE-accredited educational program is designed to provide all members of the multidisciplinary care team knowledge and resources to successfully address practical issues and barriers faced in integration of immunotherapies into the treatment of renal cell carcinoma (RCC).

The ACCC education program on Optimizing Outcomes for Urothelial Carcinoma in the Community Setting is designed to provide all members of the multidisciplinary care team knowledge and resources to successfully address practical issues and barriers faced in integration of immunotherapy and other novel targeted therapies into the treatment of advanced urothelial carcinoma. Audio-guided Web Course (CME/CNE provided – no CPE, no MOC) – 1 credit hour.

Organized around four case studies, the discussion will focus on current clinical evidence for optimal selection of immunotherapy and use of combination therapy. Topics covered include monitoring for and managing irAEs, care coordination and communication with non-oncology specialists, and assessment of institution- or practice-specific gaps in IO integration. Shared decision-making, toxicity management, reimbursement, and survivorship will also be discussed. This activity is supported by an educational grant from Bristol Myers Squibb.